Company BioXcel Therapeutics, Inc.

BTAI

US09075P1057

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-12-13 EST			5-day change	1st Jan Change
0.4121 ^USD	+0.54%		+1.05%	-86.03%

11-21	Bioxcel Therapeutics, Inc. Appoints David Mack to the Board, Compensation Committee and Capital Raising Committee	CI
11-21	Bioxcel Therapeutics, Inc. Announces Fifth Amendment to Credit Agreement	CI

Business description: BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Companyâs most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Number of employees: 74

Sales by Activity: BioXcel Therapeutics, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023
Pharmaceuticals	-	-	-	375K	1.38M

See all business segments

Geographical breakdown of sales: BioXcel Therapeutics, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023
United States	-	-	-	375K	1.38M

See all geographic segments

Managers: BioXcel Therapeutics, Inc.

Director	Title	Age	Since
Vimal Mehta CEO	Chief Executive Officer	63	2017-04-30
Richard Steinhart DFI	Director of Finance/CFO	66	2017-09-30
Vincent O'Neill CTO	Chief Tech/Sci/R&D Officer	55	2017-06-30
Frank Yocca CTO	Chief Tech/Sci/R&D Officer	68	2017-05-31
Brennan Doyle IRC	Investor Relations Contact	-	-

See BIOXCEL THERAPEUTICS, INC. governance

Members of the board: BioXcel Therapeutics, Inc.

Manager	Title	Age	Since
Peter Mueller CHM	Chairman	68	2017-07-31
Sandeep Laumas BRD	Director/Board Member	56	2017-08-31
Vimal Mehta BRD	Director/Board Member	63	2017-03-31
Michal Votruba BRD	Director/Board Member	58	2019-03-06
June Bray BRD	Director/Board Member	70	2021-02-28
Michael Miller BRD	Director/Board Member	67	2021-12-31
David Mack BRD	Director/Board Member	53	2024-11-20

Composition of the Board of Directors

Shareholders: BioXcel Therapeutics, Inc.

Name	Equities	%	Valuation
BioXcel Corp. 15.90 %	7,685,501	15.90 %	3 M $
Vanguard Global Advisers LLC 2.485 %	1,201,377	2.485 %	491 363 $
BlackRock Institutional Trust Co. NA 0.7375 %	356,559	0.7375 %	145 833 $
Geode Capital Management LLC 0.6164 %	298,043	0.6164 %	121 900 $
Peter Mueller 0.4811 %	232,597	0.4811 %	95 132 $

List of BIOXCEL THERAPEUTICS, INC. shareholders

Company details: BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc.

555 Long Wharf Drive 12th floor

06511, New Haven

+475 238 6837

http://www.bioxceltherapeutics.com

address BioXcel Therapeutics, Inc.(BTAI)

Other Pharmaceuticals

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
BIOXCEL THERAPEUTICS, INC.	+0.54%	+1.05%	-87.12%	-98.06%	17.52M
ELI LILLY AND COMPANY	+0.87%	-4.55%	+32.07%	+217.51%	704B
NOVO NORDISK A/S	-3.89%	-4.01%	+12.24%	+97.87%	488B
JOHNSON & JOHNSON	+0.26%	-1.80%	-5.89%	-12.96%	352B
ABBVIE INC.	+0.10%	-1.60%	+12.36%	+37.04%	306B
MERCK & CO., INC.	+0.74%	-1.06%	-4.77%	+38.93%	256B
ROCHE HOLDING AG	-0.90%	-1.48%	+0.22%	-32.53%	231B
ASTRAZENECA PLC	-0.95%	-1.75%	+0.75%	+26.92%	208B
NOVARTIS AG	-0.36%	-2.30%	+1.19%	+17.71%	198B
AMGEN INC.	-1.26%	-0.72%	-3.91%	+28.02%	147B
Average	-0.67%	-1.09%	-4.29%	+32.04%	289.17B
Weighted average by Cap.	-0.73%	-1.63%	+10.00%	+77.29%